Tau is a microtubule (MT)-associated protein, which precisely localizes to the axon of a mature neuron. Although it has been widely used as an axonal marker, the mechanisms for its axonal localization have been elusive. This might be largely due to the lack of an experimental system, as exogenously expressed tau, such as GFP-tau, mis-localizes to the soma and dendrites. In this study, we found that the expression of endogenous tau and its axonal localization in cultured rat hippocampal neurons mainly occur during early neuronal development and are coupled. By mimicking this early expression, we demonstrate that exogenously expressed human tau can be properly localized to the axon, thereby providing the first experimental model to study the mechanisms of tau localization. Using this model, we obtained surprising findings that the axonal localization of tau did not require the MT-binding domain nor correlate with the MT-binding ability. Instead, we identified a transport mechanism mediated by the proline-rich region 2 (PRR2), which contains a number of important phosphorylation sites.
INTRODUCTION
Tau is a microtubule (MT)-associated protein (MAP) localized in the axon of a neuron in normal physiological conditions (Binder et al., 1985; Peng et al., 1986; Brion et al., 1988; Migheli et al., 1988; Trojanowski et al., 1989) . In contrast, in Alzheimer's disease (AD) and related disorders, tau mis-localizes to the soma and dendrites and forms neurofibrillary tangles.
Understanding this dramatic alteration is key to understand the pathogenesis of AD, as tau pathology is unambiguously linked to neurodegeneration from pathological and genetic evidence (Gómez-Isla et al., 1997; Delacourte et al., 1999; Ghetti et al., 2015) . To do so, we need to understand how normal tau is localized to and maintained in the axon and how these mechanisms are impaired. Previous studies have made considerable efforts to study and understand the mechanisms for the axonal localization of tau. These studies have revealed essentially two major mechanisms. First, tau is transported to the axon by MT-and motor protein-based mechanisms (Utton et al., 2005; Falzone et al., 2009; Scholz and Mandelkow, 2014) . Second, MT-based filter situated near or in the axon initial segment restricts tau from entering the soma while allowing it to go into the axon (Li et al., 2011) .
However, one big challenge remaining in studying these mechanisms is to localize exogenous tau to the axon, where endogenous tau localizes exclusively (Mandell and Banker, 1996) . When tau is expressed in cultured neurons by transfection, it typically distributes uniformly throughout the cells (Xia et al., 2016) , such that the major population of tau remains in the soma and dendrites (see Fig. 1B ). This "mis-localization" makes it difficult to study axonal localization mechanisms of tau in a precise manner. We therefore set to tackle this challenge and establish a good experimental model for studying tau localization.
In our accompanying paper, we showed that tau mRNA expression is high during prenatal to the first week of postnatal development in mice. We also demonstrated that expressing human tau in the same manner as endogenous tau results in its axonal localization like endogenous tau in knock-in mice, whereas human tau expressed beyond the developmental period mis-localizes to the soma and dendrites in tau transgenic mice. In this paper, we show that this holds true in cultured neurons, such that exogenous human tau can be localized to the axon only when it is expressed early during neuronal development. Using an inducible expression system, we were able to establish an experimental model in which exogenous tau is colocalize with endogenous tau in the axon in both developing and matured neurons. With this model, we show novel findings on the relationship between MT-binding and axonal localization of tau, the involvement of the proline-rich region in tau localization, and how phosphorylation affects the localization and MT-binding.
MATERIALS AND METHODS

Neuronal culture
Dissociated cultures of embryonic (E17~18) rat hippocampal neurons were prepared from female timed pregnant rats as previously described (Misonou et al., 2008) with minor modifications. Briefly, dissected hippocampi were digested in 0.25% trypsin for 15 min at 37°C, dissociated by pipetting, and then plated onto glass coverslips coated with 1 mg/ml poly-Llysine at 50,000 cells/coverslip. Neurons were cultured for 3 to 14 days in vitro (DIV) in 6-well plates, on the bottom of which contained astrocyte cultures. Coverslips were lifted with wax pedestals as described by Kaech and Banker (Kaech and Banker, 2006) . Cytosine arabinoflanoside was added to the culture at 2 DIV to prevent the growth of non-neuronal cells on the coverslips. All animal use was approved by the institutional animal care and use committee.
DNA constructs
Human tau cDNA corresponding to the 0N4R variant (1 -363 amino acid residues) was amplified and cloned into pRK172 using NdeI and EcoRI sites. For the deletion mutants, PRR2 and MTBD, corresponding regions (140 -185 amino acid residues for PRR2 and 186 -309 for MTBD) were removed using QuickChange mutagenesis. The coding regions of tau wildtype and mutants were amplified using PCR and cloned into pAcGFP (Clontech). Synthesized phospho-mimetic and dephospho-mimetic fragments (eurofins Genomics) were introduced into SacII and PstI site of pAcGFP-Tau. Resultant AcGFP-tau and mutants (GFP-tau hereafter) was then amplified using PCR and cloned into pLVSIN lentiviral vector (Clontech), of which CMV promoter was replaced with the TRE3GS element/promoter from pTetONE (Clontech) .
Lentiviral vectors
The production of lentiviral particles was carried out as described previously (Chen and Okayama, 1987) . HEK Lenti-X 293T cells were maintained in Dulbecco's Modified Eagle Medium (Nacalai Tesque) with 10 % Fetal Bovine Serum (SIGMA), 1 μg/ml penicillin and streptomycin in 5% CO2 at 37°C until use. Cells were re-plated at 1 x 10 6 cells per 10 cm culture dish before a day of transfection. Lentiviral plasmids (6 µg of pRSV-Rev, pMD2.G, and pMDLg/p RRE plasmids from Addgene #12253, 12259, and 12251, respectively) were mixed with 12 µg of pLVSIN containing GFP-tau and 12 µg of pRRLSIN.cPPT.PGK-GFP.WPRE (Addgene #12252), of which EGFP was replaced with Tet3G (Clontech). The mixture was then mixed with 50 µl of 2.5 M CaCl₂, and supplemented with sterilized water to adjust the volume to 500 µl. They were incubated for 20 min at room temperature (~25°C) after being mixed with 2x BES-buffered saline (50 mM BES sodium salt, 280 mM NaCl, 1.5 mM Na2HPO4, pH6.95). Transfection mixture was added onto cells, which were then transferred to a 3% CO2 incubator. Next day (after about 16-20 h), the culture medium was exchanged with 10 ml of neuronal culture medium. Transfected cells were transferred to 5% CO2 incubator and incubated for 2 days. Culture medium was collected and filtered through a 0.45 µm filter unit into a 15 or 50 ml conical tube. Collected lentiviral solution was kept at 4℃ for short-term preservation or at -80℃ for long-term storage. For lenti virus titer measurement, p-24 lenti virus titer kit (TaKaRa) was used.
Inducible expression of tau
At the day of plating, hippocampal neurons were infected with the lentiviral solution at 10 ~ 50 MOI overnight. Briefly, coverslips with neurons were transferred to new 6-well plates with 1~1.5 ml of astrocyte conditioned media in each well. The conditioned media were prepared as described previously (Misonou and Trimmer, 2005) . After the overnight incubation, the media were replaced with fresh conditioned media with 1 µg/ml doxycycline for expression induction. Coverslips were transferred back to the original 6-well plates with astrocytes after 1 h induction.
Immunofluorescence labeling
Neurons were fixed in 4 % Paraformaldehyde/PBS for 20 min. Blocking and permeabilization was done in 0.2% fish skin gelatin/0.1 % Triton X-100/TBS. Primary and secondary antibodies were diluted in the same buffer and applied in separate incubation steps of 1 h and 45 min, respectively. Coverslips were mounted on glass microscope slides using ProLong Gold antifade reagent (Thermo Fischer Scientific). We used the following primary antibodies (and dilutions): rabbit anti-rodent tauN raised against the peptide (DTMEDHAGDYTLLQDEG) corresponding to the N-terminal potion of mouse tau (serum at 1:1,000), rat anti-total tau (RTM38) raised against purified recombinant human tau (),
Localization analysis
The steady-state localization of tau and other marker proteins was documented using a Olympus IX73 microscope with a 60x/1.42 NA objective lens and Andor Zyla5.5 camera, or a Carl Zeiss ApoTome system with a 63x/1.4 NA lens. Line scan analysis of fluorescence intensities was performed using ImageJ.
Fluorescence recovery after photobleaching (FRAP)
Neurons expressing GFP-tagged proteins were imaged using an Olympus FV-1000 microscope equipped or Carl Zeiss LSM 700. Images were taken every 1 s. Photobleaching was induced by applying the 450 nm laser to a circular (3.5 µm diameter) or a rectangular spot at 100% laser power for 200 ms. Fluorescence intensity was measured using ImageJ, corrected for background fluorescence and the overall bleaching due to imaging, and normalized for the maximum and minimum fluorescence intensities.
Microtubule-binding assay
Recombinant tau proteins were purified from Escherichia coli (E. coli) transformed with pRK172 vectors encoding his-tagged human tau and deletion mutants, as previously described (Xie et al., 2014) . The purity was verified with SDS-PAGE and Coomassie brilliant blue staining. Microtubules were prepared as described previously with minor modifications (Planel et al., 2007) . Briefly, mouse brains were homogenized in MT stabilization buffer (1 mM MgSO4, 1 mM EGTA, 0.1 mM DTT, 0.5% Triton X100, 10% glycerol, 100 µM taxol, 2 mM GTP, protease/phosphatase inhibitors, and 0.1 M MES, pH 6.8). After a brief centrifugation to remove debris, the supernatant was then centrifuged at 135,000 x g for 15 min at 2°C. The resultant pellet was resuspended in the MT stabilization buffer containing 0.5 M NaCl to strip endogenous tau from microtubules and centrifuged again. The pellet was resuspended in the MT stabilization buffer, and this MT fraction was used for the binding assay immediately.
Purified tau protein (250 nM as the final concentration) and 100 µl of the MT fraction were mixed and incubated on ice for 30 min. The mixture was centrifuged at 135,000 x g for 20 min at 2°C. The levels of tau in the supernatant (MT-unbound fraction) and in the pellet (MT-bound fraction) were quantified using Western blotting with purified recombinant tau as standards.
Experimental Design and Statistical Analysis
All statistical analyses were performed on GraphPad Prism software (GraphPad Software, Inc. CA, USA). Power analysis was performed using G*Power (Faul et al., 2007 (Faul et al., , 2009 ) with parameters taken from previous reports or similar experiments. FRAP data were background subtracted, compensated for bleaching from imaging, and normalized to make the minimum and maximum 0 and 1, respectively (Jensen et al., 2017) . The recovery phase from the minimum were fitted with the one-phase association model: Y= Y0 + (Plateau -Y0) x (1 -10 -k x X ). The difference of the fitted curves among different tau variants or in different areas in neurons were analyzed with F-test for the null-hypothesis that a curve with shared parameters (slope k and Plateau) fits better than those with different parameters for each data set. We also fitted data from individual neurons and obtained averaged slope and Plateau for each mutant. For Fig. 3B , the recovery data were fitted with a one-dimensional diffusion model (Ellenberg and Lippincott-Schwartz, 1999) to obtain the estimate of diffusion coefficient for WT tau.
For the analysis of axonal transport, intensity profiles over the bleached area from three neurons were obtained from right after photobleaching and 10 s (WT tau) or 5 s (DPRR2) later and averaged for each time point. The area between these two curves was then measured at proximal and distal areas within the bleached area and compared using paired
For the MT-binding data, we normalized MT-bound fractions to those of WT tau in each experiment to compensate for the variability in MT stability. The normalized data from all tau variants were analyzed at once using ANOVA with Dunnett's post hoc tests to minimize multiple comparisons.
To compare the localization of tau mutants relative to that of endogenous tau, we measured average fluorescence intensities of expressed tau in a dendrite and the axon and computed the ratio of axonal over dendritic signals. The value was normalized to that of endogenous tau in the same neuron. We obtained normalized ratios from 6~8 neurons for each tau mutant from at least two independent cultures. The averages were compared to that of WT tau using ANOVA with Dunnett's post hoc tests.
RESULTS
A new experimental system in which exogenous tau is localized to the axon
Tau is commonly used as an axonal marker because of its precise localization to the axon, as shown in Fig. 1A . To study the mechanism of this axonal localization, researchers have used cultured neurons to express exogenous tau with a tag, such as GFP. However, expressed tau is uniformly expressed in the soma, dendrites, and the axon (Fig. 1B) , such that one cannot use this kind of experimental systems to study the precise localization mechanisms. We therefore sought to address this issue and to establish an experimental system in which exogenous tau localizes to the axon.
Typically, cultured neurons are transfected at 5 ~ 10 DIV, and tau expression is induced constitutively by a strong promoter such as a CMV promoter. However, it has been reported that endogenous tau is highly expressed and localized to the axons in immature neurons (Mandell and Banker, 1996) . We confirmed that tau is preferentially localized to the axon even in the stage 3 neurons, which are right after the axon specification period (Fig. 1C ).
We also found that the relative intensity of tau immunoreactivity is high at 3 DIV and decline as neurons become mature ( Fig. 2A ). Based on these observations, we hypothesized that for exogenous tau to be properly localized to the axon it needs to be expressed transiently during early development ( Fig. 2B ).
To test it, we constructed Tet-ON lentiviral vectors, with which the expression of exogenous tau can be controlled pharmacologically via the tetracycline transactivator (Urlinger et al., 2000) . Cultured neurons were infected with lentiviral particles at 0 DIV and treated with doxycyclin to induce the expression for 1 h at 1 DIV. This transient expression resulted in axon specific localization of human tau (Fig. 2C ). Although the expression was induced only for the short period of time (1 h), GFP-tau was readily detected even in the 14 DIV neurons, indicating that the turnover of tau is slow as previously implicated (Mercken et al., 1995; Morales-Corraliza et al., 2009; Yamada et al., 2015; Sato et al., 2018 ). Furthermore, we were able to recapitulate the developmental localization of tau. As shown earlier in Fig. 1C , endogenous tau is concentrated to the distal axon even in stage 3 neurons. GFP-tau expressed under the Tet-ON system also showed this preferential localization to the axon and co-localization with endogenous tau (Fig. 2D ).
We then tested if it is the timing of expression or the briefness of the expression by expressing GFP-tau transiently at 7 DIV. Fig. 3A shows the axonal localization of GFP-tau in 14 DIV neurons, in which the expression was induced at 1 DIV. Line scan analysis indicates that GFP-tau is co-localize with endogenous tau in the axon but not with MAP-2 in and dendrites ( Fig. 3B ). In contrast, GFP-tau was readily detected in the soma with MAP-2, when expressed at 7 DIV ( Fig. 3C ). Line scan analysis also revealed that GFP-tau was mostly in dendrites rather than the axon in these neurons (Fig. 3D ). These results support our hypothesis and demonstrate a novel experimental system to study the mechanisms for the axonal localization of tau, and presumably for its mis-localization.
Molecular mobility of exogenous tau unraveling its MT-binding
Diffusional motion and MT-binding of tau have been studied in neurons using fluorescence recovery after photobleaching (FRAP) and single-molecule tracking techniques (Konzack et al., 2007; Weissmann et al., 2009; Janning et al., 2014 ). Here we also tested how exogenous tau behaves in our experimental system using FRAP. We observed somewhat slow mobility of GFP-tau in distal axons in neurons at 3 DIV ( Fig. 4A and 4B ) with the half time of recovery at about 15 s. We fitted the recovery phase with a one-dimensional diffusion model (Ellenberg and Lippincott-Schwartz, 1999) and obtained the diffusion coefficient of 0.15 ± 0.01 µm 2 /s ( Fig.   4B ), which is much smaller than that previously reported. This slow mobility in the axon persisted during the maturation of neurons, such that there were only small differences in FRAP at 3, 7, and 14 DIV (Fig. 4C ). In contrast, the mobility of GFP-tau in the soma changed substantially and was significantly decreased between 3 and 14 DIV ( Fig. 4D and 4E ). These results indicate that GFP-tau binds to MTs more stably in the axon than previously reported, and that MT-binding of tau is facilitated in the soma.
To test if the mobility of GFP-tau reflects its MT-binding in situ, we generated tau lacking the MT-binding domain (MTBD) ( Fig. 5A ) and investigated its MT-binding in an in vitro assay ( Fig. 5B ) and in FRAP in neurons. As expected, recombinant tau lacking MTBD (tau DMTBD) purified from E. Coli exhibited significantly reduced MT-binding (p< 0.0001 with q (30) = 7.145 using ANOVA with Dunnett's test, analysis done altogether with all the mutants as shown in Table 1 ), whereas wild-type tau (WT tau) was detected mostly in the MT-bound fraction ( Fig. 5C , and see Table 1 for details). We then performed FRAP to probe their MT binding in the axons of cultured neurons. As shown in Fig. 5D , in contrast to the slow recovery of wild-type tau, GFP-tagged DMTBD showed a virtually complete and faster recovery. When the normalized fluorescence signals were fitted with single exponential functions ( Fig. 5E ), the slopes and the immobile fraction differ significantly between WT tau and tau DMTBD (Slope, 0.062 ± 0.004 vs 0.267 ± 0.024; immobile fraction, 0.37 ± 0.02 vs 0.12 ± 0.03, both p< 0.0001) (see Table 2 for details). Regression analysis also showed a significant difference in slope (p< 0.0001 with F (1, 715) = 295.4). These characteristics (p= 0.75 for WT tau 3 vs 7 DIV, and p= 0.10 for DMTBD using ANOVA with Sidak's post hoc tests) and the difference (p< 0.0001, WT tau vs DMTBD at 7 DIV with regression analysis) were maintained in more mature neurons at 7 DIV for both WT tau and DMTBD. These results suggest that WT tau binds to MTs in the axon and that that DMTBD diffuses freely and does not efficiently bind to microtubules.
Axonal localization of GFP-tau independently of the microtubule-binding
While we perform FRAP, we realized that DMTBD localized to the axon like WT tau in immature neurons at 3 DIV ( Fig. 6A ) and more mature neurons at 7DIV (Fig. 6B ). This was very surprising because of the following reasons. First, it has been thought that the axonal localization of tau is achieved by its preferential binding to axonal MTs to dendritic MTs (Kanai and Hirokawa, 1995; Weissmann et al., 2009) . Second, MT-dependent transport systems have been also implicated (Utton et al., 2005; Falzone et al., 2009; Scholz and Mandelkow, 2014) . Third, it has been proposed that a MT-based molecular filter prevents tau from reentering the soma from the axon and therefore maintains the axonal localization of tau (Li et al., 2011) .
To further investigate the localization of DMTBD, we performed double immunolabeling with endogenous tau. It also revealed that DMTBD co-localizes with endogenous tau in the axon at 3 DIV ( Fig. 6C ). Since the axonal localization was evident with the direct GFP signals ( Fig. 6A and 6B ), the apparent axonal localization is not due to preferential labeling of axonal tau molecules in immunocytochemistry. It retained the axonal localization even in more mature neurons at 14 DIV (Fig. 6D ). The axonal localization is also not a general tendency for any cytosolic proteins, as mKate2-tagged MAP-2 ( Fig. 2C ) and GFP (Fig. 5B ) did not exhibit the axonal accumulation like WT tau and DMTBD. Therefore, these results suggest that the preferential localization of tau to the axon does not require MTBD and stable MT-binding.
Axonal localization mediated by the proline-rich region 2 (PRR2)
Since the deletion of MTBD did not affect the localization of tau, we aimed to determine the region of tau determining its axonal localization using a series of deletion mutants. We found that removing the proline-rich region 2 (DPRR2) (see Fig. 5A ) resulted in a uniform distribution of tau in the soma, dendrites, and the axon of neurons ( Fig. 7A) , which is strikingly different from WT tau and DMTBD (Fig. 6A ). This mis-localization of DPRR2 is not due to its increased MT-binding. The biochemical MT-binding assay revealed that DPRR2 exhibits a significant albeit slight loss of MT-binding (p= 0.0295 with q (30) = 2.887) ( Fig. 7C and Table 1 ).
Interestingly, deletion of both PRR2 and MTBD resulted in a greater reduction of MT-binding than DMTBD and almost complete loss of MT-binding (p<0.0001 with q (30) = 17.95 against WT) ( Fig. 7C and Table 1 ). FRAP analyses of DPRR2 also showed significant increases in the recovery rate (0.075 ± 0.004 vs 0.1389 ± 0.0157, p= 0.0087) and the mobile fraction (0.6307 ± 0.0234 vs 0.7814 ± 0.0235, p= 0.0011) compared to WT tau ( Fig. 7B and Table 2 ), suggesting that PPR2 participates in MT-binding as previously indicated (Butner and Kirschner, 1991; Gustke et al., 1994; Goode et al., 1997) .
To further quantify the effect of PRR2 deletion on the localization, we performed double-immunolabeling of DPRR2 and endogenous tau. As shown in Fig. 7D, DPRR2 localization was dramatically different from that of endogenous tau. This difference was also evidenced by the line scan analysis of fluorescence signals (Fig. 7E ). We also computed the ratios of axonal signals over dendritic signals for endogenous and exogenous tau (DMTBD and DPRR2) and normalized the ratio of exogenous tau to that of endogenous tau in each neuron. Therefore, a good colocalization of exogenous tau with endogenous tau would result in a value close to one. As shown in Fig. 7F , WT tau, which exhibits a similar enrichment in the axon as endogenous tau (Fig. 2D ), had the ratio close to one. However, DPPR2 tau showed a significantly smaller ratio (0.9069 ± 0.1478 vs 0.4851 ± 0.0675, p= 0.0199, q (28) = 2.989, ANOVA with Dunnett's post hoc test, analysis done altogether with all the mutants as shown in Fig. 11G and Table 3) , showing that it is not enriched in the axon. In contrast, there was no difference between WT and DMTBD (p= 0.6788). This mis-localization was maintained in more mature neurons as shown in Fig. 7 . While WT tau was only detected in the axon with endogenous tau (Fig. 8A and 8B ), DPPR2 was present in the soma and dendrites as well as the axon (Fig. 8C and 8D) . These results suggest that PRR2 is critical for the axonal localization of tau.
Active transport of tau to the axon
We initially considered three plausible mechanisms for tau to localize to the axon (Fig. 9A ).
One obvious mechanism was that axonal MTs traps tau in the axon. However, we reject this model because DMTBD was diffusible anywhere in neurons even near the tip of the axon, where it is highly accumulated ( Fig. 9B and 9C ). The diffusivity was also comparable in dendrites and the axon (Fig. 9D ). Also, its high diffusivity indicates that DMTBD does not bind to any large structures, such as actin filaments and neurofilaments. Therefore, we sought to test the alternative models.
It has been proposed that the axon initial segment functions as a size filter for cytoplasmic proteins and organelles. Mandelkow and colleagues have also proposed that there is a filter or barrier which allows the entrance of tau into the axon but prevent it from returning to the soma (Li et al., 2011) . To test If there is a barrier/filter like this, we performed FRAP of DMTBD in the soma. Neurons expressing DMTBD at 3DIV (Fig. 9E ) were subjected to somatic FRAP. We expected that there was no significant recovery of DMTBD in the soma, as axonal DMTBD would not re-enter the soma. However, when the entire somatodendritic region was photobleached as shown in Fig. 6F , there was a rapid and substantial recovery of the somatodendritic fluorescence as well as a concomitant decrease of the axonal fluorescence (Fig. 9G ). This suggests that tau DMTBD is freely diffusible from the axon to the soma and dendrites, in spite of its overall axonal localization. These results do not support the barrier/filter model. We next sought to examine the directional transport of tau to the axon using FRAP.
Although it has been previously proposed that tau is transported by a motor-MT transport system in the axon, there must be a MT-independent transport of tau to the axon. To do so, GFP-tau was photobleached in the beginning part of the axon as shown in Fig. 10A . This allowed us to monitor the flow of fluorescent molecules from proximal and distal sides and to test if there is a directional motion of tau. We found that WT tau exhibited an asymmetric flow after photobleaching, such that the fluorescence signal recovered preferentially from the somatic side of the bleached area (Fig. 10A) . In contrast, DPRR2 exhibited more symmetric recovery (Fig. 10A ).
To better quantify this difference, we performed FRAP in the axon where the thickness and fluorescence signals are uniform (Fig. 10B) . The recovery was monitored using a line profile function and plotted against the distance. As shown in the line graphs, the recovery was asymmetric for WT tau but not for DPRR2. We measured the area under the curve in the proximal and distal bleached areas as indicated in Fig. 10C . This showed that the recovery was significantly greater (p= 0.0012 with t (4) = 9.841 using repeated measures two-way ANOVA with Sidak's post hoc tests, n= 3) in the proximal side of the bleached area than the distal side for WT tau, whereas no significant difference was observed for DPRR2 (p= 0.7280).
Taken together, these results suggest that DPRR2 is necessary for the axonal localization of tau and the directional transport of tau to the axon.
Phosphorylation of PRR2 on MT-binding and axonal localization
PRR2 contains several phosphorylation sites, which are known to be hyper-phosphorylated in neurons in AD patients. Based on our results that PRR2 is important for the axonal localization of tau, and because tau is mis-localized in affected neurons in AD, we hypothesized that the phosphorylation states of PRR2 impact the localization of tau. To gain insight on this, we first generated tau, of which all 8 putative phosphorylation sites in PRR2 (Fig. 11A ) are replaced with either alanine (Tau PRR2_Ala) to mimic dephosphorylation or glutamate (tau PRR2_Glu) as pseudo-phosphorylation. In the biochemical assay, PRR2_Glu showed a small decrease in MT-binding (p= 0.0005 with q (30) = 4.503), whereas PRR2_Ala was found virtually only in the bound fraction and indistinguishable from WT (Fig. 11B ). They also showed very different characteristics in FRAP. Tau PRR2_Glu exhibited faster recovery compared to WT tau in axons, which is similar to DPRR2 (Fig. 11C) . Surprisingly, tau PRR2_Ala showed a dramatic reduction in FRAP with a significantly reduced slope compared to WT (p= 0.013), which indicates its stable binding to MT in situ. Since the deletion of PRR2 did not abolish MT-binding per se, these results suggest that phosphorylation of PRR2 strongly regulates MT-binding of tau in neurons.
These mutants both exhibited abnormal axonal localizations. PRR2_Ala was highly accumulated in the soma, unlike WT tau and DPRR2 (Fig. 11D) , which was also apparent with the double immunolabeling with endogenous tau (Fig. 11E) . Line scan analysis clearly revealed that PRR2_Ala is stuck in the soma and proximal dendrites and cannot travel further ( Fig. 11F) , presumably due to its stable binding to MTs. PRR2_Glu was similar with DPRR2 in localization as shown in Figs. 11D, 11E , and 11F, such that it failed to accumulate in the distal axon. It also failed to show the asymmetric recovery in in the axon in FRAP (data not shown) as DPRR2 did. We also compared the axon/dendrite signal ratio normalized to that of endogenous tau. Both PRR2_Ala and PRR2_Glu had significantly lower ratio (0.5035 ± 0.0841, p= 0.021; 0.5028 ± 0.0770, p= 0.0268, respectively) than WT tau and comparable ratio to that of DPRR2 ( Fig. 11G and Table 3 ). Therefore, hyper-phosphorylation could disrupt the function of PRR2 and PRR2-dependent axonal localization of tau, whereas hypophosphorylation enhances the MT-binding and also interfere the axonal localization.
DISCUSSION
In this paper, we demonstrated a new cellular model to study the mechanisms for the axonal localization of tau. Our experimental model is unique in that exogenously expressed tau, such as GFP-tagged human tau, can be highly localized to the axon and colocalize with endogenous tau. This is different from previously used culture models, in which exogenous tau is constitutively expressed and distributes throughout the cell uniformly. Therefore, we believe that our experimental system provides a new platform to study the mechanisms of tau localization and mis-localization.
In combination with FRAP, our experimental model also allowed us to study MTbinding of tau in the axon in situ. The MT-binding of tau mutants assessed by FRAP was in a good agreement with that obtained in the in vitro biochemical assay. One potential caveat in the FRAP assay would be that excess amount of exogenous tau saturates MTs and results in an augmented pool of free tau. Our results indicate that this is the case with our system. First, the diffusivity of WT tau estimated from our FRAP analysis was smaller than that expected when a large portion of tau molecules is free. Second, PRR2_Ala mutant exhibited a negligible level of freely diffusible tau, while we observed comparable levels of direct GFP fluorescence from this mutant and all other tau constructs. Also, expression of WT tau did not affect the axonal localization of endogenous tau. These results suggest that expressed tau does not saturate MTs in our experimental model.
With the in situ MT-binding assay, we confirmed that both MTBD and PRR2 participate in MT-binding with MTBD being as the primary binding site (Goode et al., 1997) . The deletion of PRR2 showed a modest effect on MT-binding in vitro and in situ. However, PRR2_Ala exhibited a significant increase in MT-binding in the in situ assay, indicating that the phosphorylation state of PRR2 impacts MT-binding, as previously reported (Kiris et al., 2011; Schwalbe et al., 2015) . This effect was not observed in the biochemical assay because virtually all WT tau was already found in the MT-bound fraction, such that the binding could not be further improved in this assay. Recombinant WT tau, which is not phosphorylated, may just behave exactly like PRR2_Ala in vitro. In contrast, WT tau and PRR2-Ala were completely different from one another in FRAP. This suggests that WT tau in neurons is phosphorylated to some extent and exhibits more dynamic binding to MTs. This is consistent with that embryonic tau is highly phosphorylated in vivo.
PRR2_Ala also mis-localized to the soma and dendrites robustly. This suggests that tight and stable binding of dephosphorylated tau prevents it from going far in the axon. With that WT tau in neurons has reduced MT-binding, phosphorylation of PRR2 might be necessary for the initial transport of tau to the distal axons. Although we have not been able to identify the exact phosphorylation site(s) in PRR2 responsible for MT-binding thus far, this phosphorylation of PRR2 might be the reason why our method works to localize tau to the axon. It has been shown that tau is not highly phosphorylated in mature neurons in vivo in normal conditions, whereas it is in immature neurons. Therefore, tau expressed during the developmental stages is properly phosphorylated on select sites in PRR2, not tightly bound to MTs, and efficiently transported to the axon. In fact, our data showed that WT tau in immature neurons are significantly more mobile in the soma than in mature neurons. If tau is expressed beyond the developmental period or in mature neurons, it might be dephosphorylated, tightly binds to MTs, and therefore mis-localizes to the soma and dendrites. Surprisingly, the axonal localization of tau was not dependent on its MT-binding via MTBD. DMTBD was localized to the axon with endogenous tau, despite that it did not seem to bind to MTs or any cytoskeletal structures in cells, evidenced by its rapid diffusional characteristics and the negligible level of immobile fraction in FRAP. In contrast, DPRR2 retained MT-binding but mis-localized to the soma and dendrites. Our FRAP data also indicated that the preferential transport from proximal to distal axon observed with WT tau was lost with DPRR2. Given that a large portion of molecules are readily diffusible for WT tau and DMTBD, these results suggest that there is a strong directional transport mechanism for tau, which can work against diffusional flux. In fact, we observed such directional transport of WT, which was lost with the PRR2 deletion.
It has been proposed that tau is transported to the axon by MT-dependent motors (Utton et al., 2005; Falzone et al., 2009; Scholz and Mandelkow, 2014) . Our results show that MTBD is not necessary for the axonal localization of tau, although it is critical for the stable binding of tau to MTs in vitro and in the axon. These results indicate that MT-binding mediated by MTBD is not necessary for tau transport. However, the diffusivity of DMTBD in the axon we estimated was 2.25 ± 0.33 µm 2 /s, which is still low for freely diffusible proteins. Therefore, it is possible that DMTBD binds transiently to MTs via PRR2 and/or linker protein(s), and is transported toward distal axons while repeating binding and unbinding with MTs. Our results that DMTBD retains MT-binding, presumably via PRR2, in the in vitro assay support this idea.
Alternatively, tau is transported by MT-independent mechanisms mediated by actin filaments.
It has also been proposed that a filter or barrier near the axon initial segment prevents tau from entering the soma from the axon, thereby maintaining its axonal localization. Our results with DMTBD indicate that, even when a large portion of tau re-enters the soma, the overall axonal localization can be achieved, presumably by the active transport in developing neurons. It is still possible that a barrier mechanism helps to maintain the axonal concentration of tau, particularly in mature neurons. However, based on our results of DMTBD in mature neurons, we have to conclude that this kind of mechanism is largely MTBD-independent and/or has only a minor role in establishing the axonal localization of tau.
By employing the novel experimental system, our study confirmed the importance of PRR2 and its phosphorylation in MT-binding (Kiris et al., 2011; Schwalbe et al., 2015) in situ and further demonstrated its involvement in the axonal localization of tau. The results with the phosphorylation-and dephosphorylation-mimetic mutants indicate that phosphorylation of certain sites in PRR2 impairs the transport of tau to the axon and results in similar mislocalization as the deletion of the entire PRR2. In contrast, dephosphorylation of PRR2 would greatly enhance the binding of tau to MTs in the soma, thereby slowing its transport to the axon. Therefore, for tau to be localized in the axon, it has to be properly phosphorylated in the soma to benefit from the transport mechanism without being stuck on the somatic MTs. Our results also suggest that tau expressed during the developmental period is localized to the axon, while that expressed in mature neurons mis-localizes both in culture and in vivo as demonstrated in the accompanying paper (Kubo et al.) . Considering these findings, we speculate that tau in AD is either ectopically expressed in the adulthood or becomes in excess due to the reduction of axonal MTs, and therefore mis-localized to the soma and dendrites. A, Potential models for the axonal localization of tau. The trap model assumes a stable scaffold like microtubules, which binds and traps tau (grey circles) in the axon. In the barrier/filter model, a putative barrier/filter prevents tau molecules (or complexes) from escaping from the axon, while it allows somatic tau to enter the axon. The directional transport model proposes that an active transport mechanism constitutively sends tau from the soma to the axon at a rate greater than that of tau being sent bay by diffusion.
B, FRAP of WT tau near the tip of the axon. Images before, immediately after bleaching, and 10 s after bleaching are shown. Scale bar, C, Rate of recovery from the experiment in B. The data shown are the mean ± S.E.M. and those in Fig. 3E is also shown for comparison. Curve fitting was done with an exponential function. The recovery was significantly faster in the tip than in the shaft of the axon (p< 0.0001 with F (1, 541) = 33.46 using regression analysis and F-test). This is presumably due to that the tips are typically thicker than the shaft. D, FRAP of WT tau in dendrites and axons. The data shown are the mean ± S.E.M. and those in Fig. 3E is also shown for comparison. Curve fitting was done with an exponential function.
There was a significant difference in the rate of recovery between dendrites and axons (p= 0.006 with F (1, 601) = 7.57 using regression analysis and F-test). This is also probably due to the larger volumes of dendrites than axons. 
